Publication
A Multicenter Retrospective Comparative Analysis of Therapeutic Outcomes in Multiple Myeloma Patients Receiving Varied Ixazomib Dosage Regimens.
Liang Zhao, Xiao He, Mingyang Deng, Yun Yuan, Zhiyu Su, Zhongqi Ding, Youping Liao, Chanjuan Shen, Zhongjun Huo, Zimian Luo, Zhiqin Li, Limei Fu, Ping Zhu, Xiangling Feng, Shuping Chen, Yanjuan He, Yan Zhu
- Source
- PubMed
- Retrieved
- Sep 29, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260929-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Multiple myeloma (MM) is an incurable hematologic malignancy, requiring sustained therapeutic management to mitigate disease recurrence. Ixazomib, a first-generation oral proteasome inhibitor, has exhibited substantial clinical efficacy and is widely employed in clinical practice.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available